A contract to be signed of in Cuba to introduce the Heberprot-P in Barbados.

The businessman Philip Springer, executive director of the Superior Pharmaceutical barbadian company, made a fruitful working visit to Cuba between February 23 and March 4, whose main result was the signing of a contract with the Cuban biotechnology company Heberbiotec for the introduction of the Heberprot-P in Barbados, which has the support of his government since the main recipient of this flag drug of Cuban biotechnology will be the Queen Elizabeth Hospital, although it will also be supplied to the private sector in order to benefit the cure of foot ulcers in diabetic patients and avoid their amputation.